Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity.

Conclusion. ROP regression rate after one intravitreal bevacizumab injection was 85.13%. This trial is registered with trial registration number IRCT2014101618966N2. PMID: 26491545 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/26491545?dopt=Abstract

Source: Journal of Ophthalmology - October 23, 2015 Category: Opthalmology Tags: J Ophthalmol Source Type: research